Market closedNon-fractional

Tourmaline Bio/TRML

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Tourmaline Bio

Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.

Ticker

TRML

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

New York, United States

Employees

58

Tourmaline Bio Metrics

BasicAdvanced
$329M
Market cap
-
P/E ratio
-$4.55
EPS
-
Beta
-
Dividend rate
$329M
62.171
60.712
0.043
0.106
-18.97%
-27.05%
0.92
0.92
-3.446
83.57%

What the Analysts think about Tourmaline Bio

Analyst Ratings

Majority rating from 6 analysts.
Buy

Tourmaline Bio Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$13M
-733.33%
Profit margin
0.00%
NaN%

Tourmaline Bio Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 17.71%
QuarterlyAnnual
Q4 22
Q1 23
Q4 23
Q1 24
Q2 24
Actual
-$4.40
-$5.40
-$0.81
-$0.55
-
Expected
-$4.90
-$3.50
-$0.79
-$0.67
-$0.71
Surprise
-10.20%
54.29%
2.53%
-17.71%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Tourmaline Bio stock?

Tourmaline Bio (TRML) has a market cap of $329M as of July 06, 2024.

What is the P/E ratio for Tourmaline Bio stock?

The price to earnings (P/E) ratio for Tourmaline Bio (TRML) stock is 0 as of July 06, 2024.

Does Tourmaline Bio stock pay dividends?

No, Tourmaline Bio (TRML) stock does not pay dividends to its shareholders as of July 06, 2024.

When is the next Tourmaline Bio dividend payment date?

Tourmaline Bio (TRML) stock does not pay dividends to its shareholders.

What is the beta indicator for Tourmaline Bio?

Tourmaline Bio (TRML) does not currently have a Beta indicator.

Buy or sell Tourmaline Bio stock

Buy or sell Tourmaline Bio stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing